[Risk-adapted therapy in acute myeloid leukemia].

The identification and characterization of an increasing number of chromosomal and molecular aberrations has not only increased the understanding of the pathogenesis of acute myeloid leukemia but also provides the means for a better judgment of prognosis and the direction of therapy. Together with patient-specific factors like age, co-morbidity, and performance status, an individualized risk profile can be used to select the most appropriate therapeutic strategy.